Expression and clinical significance of serum MMP‑7 and PTEN levels in patients with acute myeloid leukemia

Wu,Jiang; Song,Yu

doi:10.3892/ol.2018.7799

Expression and clinical significance of serum MMP‑7 and PTEN levels in patients with acute myeloid leukemia

Authors:
- Jiang Wu
- Yu Song
View Affiliations

Affiliations: Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Respiration, The Central Hospital of Wuhan, Wuhan, Hubei 430014, P.R. China
Published online on: January 15, 2018 https://doi.org/10.3892/ol.2018.7799
Pages: 3447-3452
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to examine the changes of serum matrix metalloproteinase‑7 (MMP‑7) and phosphatase and tension homolog (PTEN) in patients with acute myeloid leukemia (AML) at different time points following treatment. The levels of serum MMP‑7 and PTEN were measured from 80 AML patients with a diagnosis of peripheral blood, immune cell phenotype, and bone marrow puncture cytology examination. Among these, there were 20 cases of complete remission, 20 cases of primary untreated patients, 21 cases of incomplete remission, and 19 cases of relapse after remission. In addition, 20 healthy adults with normal physical examination results were enrolled as the control group. Patients were divided into different groups according to the treatment period. Serum MMP‑7 and PTEN levels in patients and the healthy control group were measured using an ELISA. Compared with the control group, the levels of MMP‑7 of 20 primary untreated patients were significantly increased (P<0.05), while there was no significant difference for the levels of PTEN in the incomplete remission group. A comparison between the control and complete remission groups revealed that the levels of MMP‑7 and PTEN in the serum samples of 21 cases of patients with incomplete remission were significantly increased (P<0.05). In addition, the content of MMP‑7 in 19 patients in relapse after remission group was significantly higher (P<0.05) than that of the complete remission and healthy control groups, while the levels of serum PTEN did not show significant changes. In conclusion, the level of serum MMP‑7 and PTEN in AML patients was closely related to the clinical stage and the degree of disease. The combination of MMP‑7 and PTEN may provide theoretical support for the accurate diagnosis, understanding of efficacy, prognosis and improvement of survival rate of AML.

View Figures

View References

1	Gallogly MM and Lazarus HM: Midostaurin: An emerging treatment for acute myeloid leukemia patients. J Blood Med. 7:73–83. 2016.PubMed/NCBI
2	Grain A, Sirvent A, Strullu M, Françoise M, Mohty M, Guillaume T, Chevallier P and Rialland F: Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: A study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). Leuk Lymphoma. 57:2937–2941. 2016. View Article : Google Scholar : PubMed/NCBI
3	Yung KW, Yung TT, Chung CY, Tong GT, Liu Y, Henderson J, Welbeck D and Oseni S: Principles of cancer staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
4	Sterling B, Cole R, Jen KK and Shieh JS: Surgical oncology in the elderly. Asian Pac J Surg Oncol. 1:83–100. 2015.
5	Lee R, Yeung AW, Hong SE, Brose MS and Michels DL: Principles of medical oncology. Asian Pac J Surg Oncol. 1:39–46. 2015.
6	Buchanan J and Tirado CA: A t(16;21)(p11;q22) in acute myeloid leukemia (AML) resulting in fusion of the FUS/TLS and ERG genes: A review of the literature. J Assoc Genet Technol. 42:24–33. 2016.PubMed/NCBI
7	Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hajime M, Shuichi Y, Makoto N, Masanori Y, Ikuko K, Atsushi K, Mutsuo S and Keiichi T: Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer. 120:2704–2709. 2007. View Article : Google Scholar : PubMed/NCBI
9	de Bont ES, Rosati S, Jacobs S, Kamps WA and Vellenga E: Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor. Br J Haematol. 113:296–304. 2001. View Article : Google Scholar : PubMed/NCBI
10	Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F and Ciuffreda L: PTEN: Multiple functions in human malignant tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
11	Hopkins BD, Hodakoski C, Barrows D, Mense SM and Parsons RE: PTEN function: The long and the short of it. Trends Biochem Sci. 39:183–190. 2014. View Article : Google Scholar : PubMed/NCBI
12	Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K, Miwa K, Sugiyama K and Sasaki T: Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer. 3:63–70. 2000. View Article : Google Scholar : PubMed/NCBI
13	Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K and Miyazaki K: Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene. 22:8662–8670. 2003. View Article : Google Scholar : PubMed/NCBI
14	Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res. 29:2513–2517. 2009.PubMed/NCBI
15	Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, Mao TL, Lin HW, Lin Chiang WH and Cheng WF: Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J. 442:293–302. 2012. View Article : Google Scholar : PubMed/NCBI
16	Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagström J and Haglund C: MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 31:149–155. 2010. View Article : Google Scholar : PubMed/NCBI
17	Mitsiades N, Yu WH, Poulaki V, Tsokos M and Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61:577–581. 2001.PubMed/NCBI
18	Sanna M, Caocci G, Vacca A, Piras E, Orrù F and La Nasa G: Daunorubicin, cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte infusion for extramedullary relapse of acute myeloid leukemia after hematopoietic stem cell transplantation. Case Rep Hematol. 2013:2580282013.PubMed/NCBI
19	Folkman J and Hochberg M: Self-regulation of growth in three dimensions. J Exp Med. 138:745–753. 1973. View Article : Google Scholar : PubMed/NCBI
20	Poon RT, Fan ST and Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 19:1207–1225. 2001. View Article : Google Scholar : PubMed/NCBI
21	Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, et al: Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila). 6:925–937. 2013. View Article : Google Scholar : PubMed/NCBI
22	Hussong JW, Rodgers GM and Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 95:309–313. 2000.PubMed/NCBI
23	Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R and Kohn EC: Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis. 15:33–45. 2012. View Article : Google Scholar : PubMed/NCBI
24	McKee C, Perez-Cruet M, Chavez F and Chaudhry GR: Simplified three-dimensional culture system for long-term expansion of embryonic stem cells. World J Stem Cells. 7:1064–1077. 2015.PubMed/NCBI
25	Bieker R, Padró T, Kramer J, Steins M, Kessler T, Retzlaff S, Herrera F, Kienast J, Berdel WE and Mesters RM: Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res. 63:7241–7246. 2003.PubMed/NCBI
26	Cheng HW, Li CW, Chan KY, Au HY, Chan PF, Sin YC, Szeto Y and Sham MK: End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia. Support Care Cancer. 23:111–116. 2015. View Article : Google Scholar : PubMed/NCBI
27	Burgucu D, Guney K, Sahinturk D, Ozbudak IH, Ozel D, Ozbilim G and Yavuzer U: Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma. BMC Cancer. 12:4812012. View Article : Google Scholar : PubMed/NCBI
28	Li L, Wang LX, Xu GL, Yang F, Gao QL, Niu H, Shi B and Jiang X: Bio-informatics analysis of renal carcinoma gene matrix metalloproteinase-7. Indian J Cancer. 53:13–18. 2016. View Article : Google Scholar : PubMed/NCBI
29	Mieszało K, Ławicki S and Szmitkowski M: The utility of metalloproteinases (MMPs) and their inhibitors (TIMPs) in diagnostics of gynecological malignancies. Pol Merkur Lekarski. 40:193–197. 2016.(In Polish). PubMed/NCBI